F2G and Shionogi released positive Phase 3 results for orally administered olorofim, moving the program back toward regulatory resubmission after an earlier FDA complete response letter rebuff. The companies reported olorofim met noninferiority versus IV-administered Ambisome (amphotericin B) in patients with refractory aspergillosis or those unsuitable for azole therapy. The primary noninferiority endpoint centered on all-cause mortality at day 42, with reported rates of 23.8% for olorofim and 24.3% for Ambisome. F2G framed this as establishing the data package needed to prepare an NDA resubmission. The underlying competitive significance is that olorofim would represent the first new systemic antifungal in more than two decades if approved, targeting a historically underserved space where resistance and toxicity have constrained options. For investors and clinicians, the release reduces key regulatory uncertainty and restarts a formal approval track—positioning Shionogi/F2G to advance toward potential label differentiation by route of administration and patient suitability.